Loading...
NPI 1831282334 · Morristown, NJ · Hematology (Pathology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Bader Pedemonte is a hematology (pathology) physician provider located in Morristown, New Jersey. This profile covers 25 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Bader Pedemonte |
| Address | 100 Madison Ave Morristown Memorial Hospital |
| City | Morristown |
| State | NJ |
| ZIP | 07960 |
| Taxonomy | Hematology (Pathology) Physician |
| NPI Enumerated | October 2, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.2M |
| Medicaid | $1.5K |
BADER PEDEMONTE is a Hematology (Pathology) Physician based in MORRISTOWN, NJ, with an NPI enumerated on 2006-10-02 (~20 years ago). The provider’s billing is overwhelmingly Medicare-driven with Total Medicare revenue of $4.2M compared with Total Medicaid revenue of $1.5K, indicating an effectively single‑payer (Medicare) footprint at scale.
Medicare revenue is highly concentrated in a few lab services: the precomputed top 3 Medicare codes account for 79.9% of this provider’s total Medicare revenue, led by 88120 at $2.4M (58.5% of Medicare revenue), followed by 88377 at $503K (12.1%) and 88108 at $385.2K (9.3%). This concentration implies most Medicare dollars flow from a small set of specialized pathology assays rather than a broad mix of general office or procedural charges.
The code mix points to a high‑throughput, lab‑centric pathology operation focused on cytopathology and molecular/in situ hybridization services: top codes include 88108 (cytopathology smears), 88120 (in situ hybridization analysis), and 88377 (single multiplex in situ hybridization probe stain interpretation). Substantial activity on flow cytometry add‑ons such as 88185 (10K claims, $220.3K) and interpretation codes like 88189 further support that this practice processes large volumes of specimen‑based diagnostic testing rather than face‑to‑face clinical visits.
This provider is a national outlier on multiple high‑revenue Medicare codes: 88120 ranks #1 of 232 providers nationally (100th percentile; extreme outlier), 88108 ranks #1 of 2113 providers nationally (100th percentile; extreme outlier), and 88377 ranks #6 of 616 providers nationally (99th percentile; extreme outlier). Those rankings indicate a dominant national position for these specific tests and suggest the provider functions as a major regional or national testing center for the corresponding assays.
Although the provider shows strong Medicare surgical pathology volume for 88305 (9.7K claims, $301.3K revenue; ranks #274 of 14580 nationally, 98th percentile; notably above typical national volume), Medicaid activity is negligible and concentrated: Medicaid revenue is $1.5K and is 100.0% attributable to 88305 (28 claims). The Medicaid rank for 88305 in‑state is #197 of 209 (6th percentile; typical, unremarkable volume), signaling a very small Medicaid presence relative to state peers despite notable Medicare surgical pathology activity.
Operationally, claim counts are substantial for specimen‑based workflows (for example 13.3K claims for 88108 and 8.8K claims for 88120), and multiple add‑on and interpretive codes (88185 10K claims, 88189 640 claims) appear throughout the top codes. These volumes are consistent with a centralized laboratory processing large numbers of cytology slides, in‑situ hybridization assays, and flow cytometry panels rather than a low‑volume clinical pathology practice.
For payer contracting and utilization management, the concentration metric (top 3 Medicare codes = 79.9% of Medicare revenue) and extreme outlier rankings on key assays suggest targeted review and contract terms should focus on in‑situ hybridization (88120, 88377), cytopathology (88108), and associated flow cytometry services. Given the near absence of Medicaid billing ($1.5K total), any Medicaid network or reimbursement strategy should recognize that this provider does not meaningfully participate in the state Medicaid market.
The mix of high national percentiles and extreme outlier status for specialized lab codes combined with minimal Medicaid activity creates a profile of a high‑volume, Medicare‑focused pathology lab that plays a major role for certain diagnostic assays nationally but remains a modest participant in the in‑state Medicaid market. Analysts should treat this provider as a specialized lab partner for Medicare populations and emphasize assay‑level benchmarking when evaluating competitive standing or negotiating agreements.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
25 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88120 | The lab analyst performs a technical lab test on a urinary tract specimen using in situ hybridization and three to five molecular probes for manual morphometric analysis, looking at the number and… | 8,830 | $280 | $2.4M |
| 88377 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a… | 3,110 | $160 | $503K |
| 88108 | The analyst prepares smears of cytopathology fluids, washings, or brushings, except for cervical or vaginal fluid, using a concentration technique and interprets his findings. Cytopathology is the… | 13,280 | $30 | $385.2K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 9,720 | $30 | $301.3K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 10,010 | $20 | $220.3K |
| 88374 | The lab analyst applies a single multiplex in situ hybridization probe stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. The lab analyst processes the slides… | 650 | $110 | $69.3K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 2,060 | $30 | $55.6K |
| 88189 | The clinician, typically a pathologist, interprets flow cytometry results of 16 or more markers. | 640 | $70 | $45.4K |
| 88184 | The lab analyst performs the technical component of a flow cytometry procedure using a cell surface, cytoplasmic, or nuclear marker to characterize cells and aid clinicians in diagnosing patients… | 470 | $70 | $32.7K |
| 88173 | The lab analyst performs the technical lab test to analyze a cytopathology specimen from a fine needle aspirate and then interprets and reports the results. | 480 | $60 | $29.2K |
Showing 1–10 of 25
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
25 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 88120 | 1 | 20 | 200 | $350 | $278K |
| 88185 | 5 | 20 | 690 | $20 | $265.7K |
| 88377 | 2 | 20 | 30 | $240 | $205.5K |
| 88374 | 2 | 10 | 190 | $170 | $191.1K |
| 88305 | 10 | 290 | 720 | $40 | $71.8K |
| 88184 | 5 | 20 | 40 | $70 | $31.3K |
| 88313 | 151 | 180 | 110 | $50 | $31.2K |
| 88312 | 133 | 170 | 90 | $80 | $26.4K |
| 88189 | 6 | 50 | 60 | $70 | $24.1K |
| G0416 | 21 | 70 | 20 | $230 | $20.6K |
Showing 1–10 of 25
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 30 | $60 | $1.5K |
How this provider's Medicaid billing volume and revenue compare to other New Jersey providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Jersey median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 197 | 210 | 1,660 | $60 | $347.9K |
Other providers in the same ZIP code as Bader Pedemonte, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ahs Hospital Corp. | NJ | General Acute Care Hospital | $0 | $155.9M |
| Practice Associates Medical Group | NJ | Internal Medicine Physician | $0 | $49.3M |
| Spring Hills At Morristown | NJ | Assisted Living Facility | $0 | $11.7M |
| Vinod Voleti | NJ | Retina Specialist (Ophthalmology) Physician | $4.1M | $0 |
| Constance Gore | NJ | Acute Care Nurse Practitioner | $1.1M | $0 |
| Tatyana Marx | NJ | Neurology Physician | $1M | $0 |
| Janet Bartov | NJ | Rheumatology Physician | $787.4K | $0 |
| David Taylor | NJ | Urology Physician | $775.3K | $0 |
| Thomas Lee | NJ | Vascular Surgery Physician | $684.3K | $0 |
| Sean Lalin | NJ | Ophthalmology Physician | $617.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.